Thông tin cho nhân viên y tế
Thuốc mới và thông tin từ Drugs.com
- May 18, 2026 — AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood…
- Cary, N.C., May 18, 2026—Chiesi USA, Inc. (key-A-zee), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration has approved Trimbow (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate; or…
- RALEIGH, N.C., May 18, 2026 /PRNewswire/ — Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas Pharmaceuticals"), focused on the development of oncology, immunology and central nervous system (CNS)…
- RALEIGH, N.C., May 18, 2026 /PRNewswire/ — Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas Pharmaceuticals"), focused on the development of oncology, immunology and central nervous system (CNS)…
- South San Francisco, CA — May 15, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza®…
- Tokyo – (May 15, 2026) – Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved by the U.S. Food and Drug Administration (FDA) for two new breast cancer indications in the neoadjuvant and adjuvant settings of patients with HER2…
- TUESDAY, May 19, 2026 — Noninvasive monitoring of low-grade prostate cancer with a urinary biomarker test could reduce the need for biopsies and serial imaging, according to a study published online April 28 in The Journal of Urology. Jeffrey J…
- TUESDAY, May 19, 2026 — In 2024, there were 3,798 dengue cases reported, 97.2 percent of which were associated with travel outside the reporting jurisdiction, according to research published in the May 14 issue of the U.S. Centers for Disease…
- TUESDAY, May 19, 2026 — Antidepressant use during pregnancy does not cause an increased risk for neurodevelopmental disorders in offspring, according to a review published in the June issue of The Lancet Psychiatry. Joe Kwun Nam Chan, Ph.D., from…
- TUESDAY, May 19, 2026 — Adults with poor mental health report worse self-rated overall health and more chronic illness, according to a study published online May 5 in PLOS Medicine. Margaret E. Kruk, M.D., M.P.H., from Washington University in St…
- TUESDAY, May 19, 2026 — A parental support package can significantly mitigate postpartum burnout among childbearing physicians in training, according to a study published online May 13 in the Journal of the American Medical Association. Atziri…
- TUESDAY, May 19, 2026 — The rates of dementia with Lewy bodies (DLB) increase with age, with a pooled incidence of 46.85 per 100,000 person-years among individuals aged 65 years or older, according to a review published online May 11 in JAMA…
Thông tin từ The Pharma Letter
- Olayan Financing Company (OFC) has made a minority equity investment in Jordan-headquartered MS Pharma, a leading pharma player in the Middle East North Africa (MENA) region that specializes in the development, production and distribution of a broad portfolio of generic and biologic therapies.
- AI is already reshaping how patients, professionals and the public find healthcare information. But who is thinking about the potential implications, the need for governance and where this might be leading?
- Texas, USA-based clinical-stage biotech Oorja Bio has announced the company’s launch and $30 million in Series A financing from its founding investor, Westlake BioPartners.
- Incyte and Edison Scientific have announced a strategic collaboration to employ Kosmos, Edison’s AI scientist, for the US biopharma’s discovery and development work.
- US allogeneic NK cell therapies developer Artiva Biotherapeutics announced the appointment of Dr Diego Miralles as president and head of research and development.
- Privately-held UK based AMR Bio has announced its launch as a clinical phase biotechnology company focused on one of the most urgent public health challenges: preventing infection in an era where antibiotics are becoming less effective.
Thông tin từ BioPharmaDive
- Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects.
- Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.
- While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments.
- Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in annual sales.
- The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next decade.
- The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.
Thông tin từ STAT News
- USAID cuts have painful outcomes for the Ebola outbreak, states sue over a new professional ed loan rule, and other health news
- The WHO defended its Ebola response, noting it's national authorities who detect outbreaks. Marco Rubio had said the WHO was 'a little late'
- It's part of Democrats' strategy to focus on health care affordability and access in drawing contrasts with Republicans ahead of the midterms.
- Are too many symptoms blamed on perimenopause? Two experts weigh in on the “First Opinion Podcast.”
- OpenEvidence CTO Zachary Ziegler said, at the STAT Breakthrough Summit West, that the company is looking beyond physician users.
- An NIH leadership vacuum has persisted for months, with 15 of the 27 institutes being led by acting directors.
Thông tin từ Nature Review Drug Discovery
- Nature Reviews Drug Discovery, Published online: 19 May 2026; doi:10.1038/s41573-026-01442-2Agonistic antibodies initiate signalling by the receptors they target, mimicking the activities of native ligands. This Review discusses the clinical successes and failures of agonistic antibodies and explains how recent mechanistic insights should broaden the scope and improve the safety and efficacy of immunotherapies based on […]
- Nature Reviews Drug Discovery, Published online: 18 May 2026; doi:10.1038/s41573-026-01449-9Autophagy has a highly complex and context-dependent role in cancer, challenging the development of autophagy-modulating strategies. This Review discusses the potential of targeting autophagy to counteract malignant transformation, prevent disease progression and enable anticancer immunosurveillance. Existing and emerging pharmacological strategies and the associated limitations are critically […]
- Nature Reviews Drug Discovery, Published online: 13 May 2026; doi:10.1038/d41573-026-00081-xTrends in the landscape of clinical trials of innovative drugs in China since 2015
- Nature Reviews Drug Discovery, Published online: 13 May 2026; doi:10.1038/s41573-026-01427-1Incretin-based therapies are transforming the treatment of obesity and related comorbidities. This Review outlines the current landscape of obesity drug development, focusing on glucagon-like peptide 1 receptor agonists, multi-receptor agonists, amylin receptor agonists and next-generation oral therapies. Key translational and biological challenges, as well as emerging […]
- Nature Reviews Drug Discovery, Published online: 12 May 2026; doi:10.1038/d41573-026-00080-yA peptide-guided strategy for kinase activation
- Nature Reviews Drug Discovery, Published online: 11 May 2026; doi:10.1038/d41573-026-00079-5Eli Lilly inks dual-payload ADCs deal